INS and Hyperglycemia: GDM patients receiving nutrition therapy with significantly or progressively lower levels of miR-330-3p may be candidates for progression to insulin therapy or future T2DM development due to progressive decline in compensatory insulin secretion in a setting of uncontrolled hyperglycaemia and increased IR, resulting in a persistent and progressive metabolic load45.